Inactive Instrument

Teligent

Equities

TLGT

US87960W2035

Teligent, Inc. : To Present At JMP Securities Life Sciences Conference On June 21, 2016

June 21, 2016 at 08:01 am EDT

BUENA, N.J., June 21, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the JMP Securities Life Sciences Conference. The Conference will take place June 21-22, 2016 at The St. Regis New York, New York, NY.

http://photos.prnewswire.com/prnvar/20151022/279641LOGO

Jenniffer Collins, Chief Financial Officer of Teligent, Inc. will present on Tuesday, June 21, 2016 at 12:00 p.m. ET.

The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.teligent.com. A replay will be available for 90 days.

About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.

Contact: Jenniffer Collins
Teligent, Inc.
(856) 697-4379
www.teligent.com

Logo - http://photos.prnewswire.com/prnh/20151022/279641LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/teligent-inc-to-present-at-jmp-securities-life-sciences-conference-on-june-21-2016-300287600.html

SOURCE Teligent, Inc.

Latest news about Teligent

Teligent, Inc. Went Out of Business	22-07-26	CI
Second Amended Liquidation Plan Approved for Teligent, Inc.	22-07-15	CI
Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-05-25	CI
Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	22-05-24	CI
First Amended Disclosure Statement Approved for Teligent, Inc.	22-04-29	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-27	CI
Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-08	CI
First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-02-28	CI
Motion for Case Conversion Filed by Teligent, Inc.	22-02-22	CI
First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	22-02-09	CI
Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	22-02-03	MT
Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-18	CI
London Shares to Open Higher as Traders Focus On Key Data	22-01-17	DJ
Hikma Pharmaceuticals to Enter Canadian Market With $46 Million Asset Acquisition	22-01-17	MT
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Hikma Pharmaceuticals PLC agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.	22-01-16	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-14	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI

Chart Teligent

Duration

Period

More charts

Company Profile

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Sector

More about the company